02082nas a2200145   4500000000100000008004100001100001800042700001800060700001300078245007900091856006100170300001200231490000700243520168600250       2023                            d1 aDalimunthe DA1 aSinambela DWI1 aLubis SR00aClinico-sociodemographic Profile of Leprosy Neuropathy in Medan, Indonesia  uhttp://jpad.com.pk/index.php/jpad/article/view/2059/1867  a142-1480 v333 a<p>Background: Leprosy neuropathy is still a serious health issue in emerging and underdeveloped nations. Nerve damage caused by leprosy that is not handled properly and quickly will cause disability. Therefore, information about characteristic of leprosy patients with neuropathy is very necessary. The purpose of this study is to identify the clinico-sociodemographic characteristics of leprosy patients who have neuropathy. Methods: &nbsp;This is a cross-sectional descriptive study that uses the consecutive sampling strategy on 21 leprosy patients who have neuropathy. Leprosy neuropathy was examined using Semmes-Weinstein monofilaments. Results: Sociodemographic characteristics were mostly in the age group 18-35 years (57.1%), male (85.7%), secondary education level (57.1%), and work as employee (33.3%). The majority of the research subjects were multibacillary (MB) type leprosy (100%), experiencing leprosy reactions (42.9%), release from treatment (RFT) (47.6%), leprosy duration &gt;12 months (57.1%), experienced symptoms of neuropathy (95.2 %), duration of neuropathy symptoms ≤ 1 year (52.4%), neuropathy location in the lower bilateral extremities (52.4%), and did not have a grade 2 leprosy disability according to WHO (90.5%). Conclusions: The majority of leprosy neuropathy patients were in the age group of 18-35 years, male, secondary education level, employee, MB type leprosy, experiencing leprosy reactions, RFT, duration of leprosy &gt;12 months, experienced symptoms of neuropathy, duration of neuropathy symptoms ≤1 year, neuropathy location in the lower bilateral extremities, and did not have a grade 2 leprosy disability according to WHO.</p>